4.325
Orasure Technologies Inc stock is traded at $4.325, with a volume of 331.64K.
It is down -0.92% in the last 24 hours and up +7.18% over the past month.
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
See More
Previous Close:
$4.37
Open:
$4.38
24h Volume:
331.64K
Relative Volume:
0.53
Market Cap:
$297.77M
Revenue:
$113.02M
Net Income/Loss:
$-75.07M
P/E Ratio:
-4.1479
EPS:
-1.0427
Net Cash Flow:
$-47.88M
1W Performance:
-2.91%
1M Performance:
+7.18%
6M Performance:
+72.51%
1Y Performance:
+41.97%
Orasure Technologies Inc Stock (OSUR) Company Profile
Name
Orasure Technologies Inc
Sector
Industry
Phone
(503) 641-6115
Address
220 E FIRST ST, BETHLEHEM, PA
Compare OSUR vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
OSUR
Orasure Technologies Inc
|
4.325 | 300.87M | 113.02M | -75.07M | -47.88M | -1.0427 |
|
ISRG
Intuitive Surgical Inc
|
426.08 | 153.29B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
157.25 | 42.86B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
MDLN
Medline Inc
|
42.97 | 36.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
ALC
Alcon Inc
|
67.11 | 33.32B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
RMD
Resmed Inc
|
218.78 | 31.68B | 5.54B | 1.52B | 1.74B | 10.37 |
Orasure Technologies Inc Stock (OSUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-23 | Resumed | Evercore ISI | In-line |
| Sep-22-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-21-20 | Initiated | Evercore ISI | Outperform |
| Aug-10-20 | Initiated | Citigroup | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
| Aug-07-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-25-20 | Initiated | Lake Street | Buy |
| Apr-21-20 | Resumed | Stephens | Equal-Weight |
| Oct-23-18 | Resumed | Raymond James | Mkt Perform |
| Jul-16-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-02-17 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-13-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-05-15 | Reiterated | Mizuho | Buy |
| May-07-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jan-23-15 | Reiterated | Mizuho | Buy |
| Jun-12-14 | Reiterated | Canaccord Genuity | Buy |
| Jun-11-14 | Reiterated | Mizuho | Buy |
| Dec-21-12 | Initiated | Mizuho | Buy |
| Aug-08-12 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-05-12 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-27-12 | Initiated | JMP Securities | Mkt Outperform |
View All
Orasure Technologies Inc Stock (OSUR) Latest News
OraSure Technologies updates highlight diagnostics focus amid shifting health trends - AD HOC NEWS
OSUROrasure Technologies Inc Latest SEC Filings - Finviz
Form 4 OraSure Technologies Inc For: 30 June By Investing.com - Investing.com Nigeria
OraSure Technologies (OSUR) director takes 3,666-share stock grant in lieu of cash - Stock Titan
Enterprise value to EBIT forward of OraSure Technologies, Inc. – MUN:EP3 - TradingView
Price to earnings forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to book forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to book forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Price to sales forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to sales forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Enterprise value to revenue forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Price to earnings forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Enterprise value to EBITDA forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
OraSure gets FDA nod for at-home STI urine collection kit - Investing.com Nigeria
3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
OraSure Technologies (OSUR) Pressured: Testing Support After Recent DeclineDay Trade Opportunities - dars.gov.et
OraSure Technologies Hits New 52-Week High of $4.36, Marking Significant Growth - MarketsMojo
OraSure Technologies Inc (OSUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OraSure Technologies Inc (OSUR) Institutional Confidence - TradingKey
OraSure Technologies Inc (OSUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
OraSure Technologies Inc (OSUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OraSure Technologies Inc (OSUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OraSure Technologies Inc (OSUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OraSure Technologies Inc (OSUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OraSure Technologies Inc (OSUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OraSure Technologies Inc (OSUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OraSure Wins FDA Clearance for At-Home STI Collection - The Globe and Mail
OraSure receives FDA clearance for home urine collection kit for STIs - Lehigh Valley Business
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now? - Yahoo Finance
FDA Clears Home Urine Collection Kit for STI Testing - Conexiant
OraSure secures FDA clearance for product seen as key to future growth - WFMZ.com
OraSure stock jumps on FDA clearance for at-home STI kit - Investing.com
OraSure stock jumps on FDA clearance for at-home STI kit By Investing.com - Investing.com South Africa
OraSure Technologies (NASDAQ: OSUR) wins FDA clearance for Colli-Pee Dx at-home urine collection kit - Stock Titan
OraSure gets FDA nod for at-home STI urine collection kit By Investing.com - Investing.com Australia
OraSure receives FDA clearance for at-home STI urine collection kit - StreetInsider
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections - The Manila Times
OraSure Technologies, Inc. Announces FDA Clearance that - GlobeNewswire
OraSure Technologies (OSUR) Slips 3.1% as Stock Tests Key Support LevelOvernight Profile - newsline.com
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? - Yahoo Finance
OraSure Technologies (OSUR) director receives 46,106-share restricted stock grant - Stock Titan
OraSure (OSUR) director Nancy Gagliano receives 46,106-share stock award - Stock Titan
OraSure Technologies (OSUR) director receives 46,106-share stock grant - Stock Titan
OraSure (OSUR) director John P. Kenny granted 46,106 restricted shares - Stock Titan
Director at OraSure (NASDAQ: OSUR) receives 46,106 restricted shares - Stock Titan
OraSure Shares Jump as Board Reset Draws Investor Focus - Bez Kabli
Earnings call transcript: OraSure Technologies Q1 2026 misses earnings and revenue forecasts - Investing.com UK
OraSure Technologies Investors Approve Expanded Stock Plan, Governance Changes - The Globe and Mail
OraSure Technologies (NASDAQ: OSUR) OKs more equity awards and board declassification - Stock Titan
OraSure Technologies Hits New 52-Week High of $4.33, Marking Significant Growth - Markets Mojo
OSUR Q1 2026 Earnings: EPS Miss by 69% Signals Operational HeadwindsFree Cash Flow Trends - newsline.com
Orasure Technologies Inc Stock (OSUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Orasure Technologies Inc Stock (OSUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boyd Steven Kyle | Director |
May 14 '26 |
Buy |
2.99 |
25,000 |
74,750 |
113,462 |
| Boyd Steven Kyle | Director |
May 12 '26 |
Buy |
2.98 |
25,000 |
74,500 |
63,462 |
| McGrath Kenneth J | Chief Financial Officer |
Mar 20 '26 |
Buy |
2.93 |
32,300 |
94,600 |
589,562 |
| EGLINTON MANNER CARRIE | President & CEO |
Mar 20 '26 |
Buy |
2.93 |
32,300 |
94,597 |
2,190,874 |
| McGrath Kenneth J | Chief Financial Officer |
Mar 13 '26 |
Buy |
3.00 |
22,021 |
66,030 |
557,262 |
| EGLINTON MANNER CARRIE | President & CEO |
Mar 13 '26 |
Buy |
3.00 |
22,022 |
66,033 |
2,158,574 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):